BeiGene, Ltd. (NASDAQ:BGNE) Given Consensus Recommendation of “Moderate Buy” by Analysts

BeiGene, Ltd. (NASDAQ:BGNE) has earned an average recommendation of “Moderate Buy” from the six brokerages that are covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $233.42.

BGNE has been the subject of a number of research reports. Citigroup increased their price target on shares of BeiGene from $269.00 to $288.00 and gave the company a “buy” rating in a report on Thursday, August 8th. Bank of America decreased their target price on BeiGene from $180.00 to $152.50 and set a “neutral” rating on the stock in a research report on Tuesday, July 9th. Finally, JPMorgan Chase & Co. upped their price target on BeiGene from $194.00 to $200.00 and gave the company an “overweight” rating in a report on Tuesday, August 20th.

Insider Buying and Selling

In other BeiGene news, COO Xiaobin Wu sold 5,556 shares of BeiGene stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $189.65, for a total transaction of $1,053,695.40. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other BeiGene news, insider Lai Wang sold 1,064 shares of the company’s stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $159.80, for a total transaction of $170,027.20. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Xiaobin Wu sold 5,556 shares of BeiGene stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $189.65, for a total transaction of $1,053,695.40. The disclosure for this sale can be found here. Insiders sold 13,210 shares of company stock valued at $2,269,721 over the last quarter. Corporate insiders own 7.43% of the company’s stock.

Institutional Investors Weigh In On BeiGene

Large investors have recently bought and sold shares of the business. Capital International Investors lifted its position in shares of BeiGene by 11.5% during the first quarter. Capital International Investors now owns 7,064,428 shares of the company’s stock worth $1,104,806,000 after purchasing an additional 727,556 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in BeiGene by 6.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,026,094 shares of the company’s stock worth $316,862,000 after buying an additional 117,905 shares in the last quarter. Capital International Inc. CA boosted its position in BeiGene by 6.0% in the 1st quarter. Capital International Inc. CA now owns 858,364 shares of the company’s stock valued at $134,240,000 after buying an additional 48,615 shares during the last quarter. Point72 Asset Management L.P. acquired a new stake in shares of BeiGene in the 2nd quarter valued at $54,412,000. Finally, First Trust Advisors LP bought a new stake in shares of BeiGene during the fourth quarter worth $39,632,000. 48.55% of the stock is currently owned by institutional investors.

BeiGene Trading Up 1.1 %

BeiGene stock opened at $198.49 on Monday. The business’s 50-day simple moving average is $177.16 and its 200-day simple moving average is $163.29. BeiGene has a 52 week low of $126.97 and a 52 week high of $215.00. The firm has a market capitalization of $19.26 billion, a PE ratio of -26.22 and a beta of 0.61. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.75 and a current ratio of 1.98.

BeiGene (NASDAQ:BGNE) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($1.15) EPS for the quarter, topping analysts’ consensus estimates of ($2.27) by $1.12. BeiGene had a negative return on equity of 14.93% and a negative net margin of 16.91%. The company had revenue of $929.20 million during the quarter, compared to analyst estimates of $810.34 million. During the same period in the previous year, the company earned ($3.64) earnings per share. The company’s quarterly revenue was up 56.1% compared to the same quarter last year. Equities research analysts forecast that BeiGene will post -5.13 earnings per share for the current year.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.